Table of Content

1. Key Insights

2. Executive Summary of Follicular Lymphoma

3. SWOT Analysis for Follicular Lymphoma

4. Disease Background and Overview
4.1. Introduction
4.2. Types of Follicular Lymphoma
4.3. Sign and Symptoms
4.4. Causes
4.5. Staging and Grading
4.6. Genetic Landscape of Follicular Lymphoma
4.7. Pathophysiology
4.8. Diagnosis

5. Epidemiology and Patient Population
5.1. Key Findings
5.2. 7MM Total Incident Patient Population of Follicular Lymphoma

6. Country Wise-Epidemiology of Follicular Lymphoma
6.1. Assumptions and Rationale – 7MM
6.2. The United States
6.2.1. Total Incident Cases of Follicular Lymphoma in the United States
6.2.2. Grade-specific Cases of Follicular Lymphoma in the United States
6.2.3. Age-specific Cases of Follicular Lymphoma in the United States
6.2.4. Stage-specific Cases of Follicular Lymphoma in the United States
6.3. EU5
6.3.1. Germany
6.3.1.1. Total Incident Cases of Follicular Lymphoma in Germany
6.3.1.2. Grade-specific Cases of Follicular Lymphoma in Germany
6.3.1.3. Age-specific Cases of Follicular Lymphoma in Germany
6.3.1.4. Stage-specific Cases of Follicular Lymphoma in Germany
6.3.2. France
6.3.2.1. Total Incident Cases of Follicular Lymphoma in France
6.3.2.2. Grade-specific Cases of Follicular Lymphoma in France
6.3.2.3. Age-specific Cases of Follicular Lymphoma in France
6.3.2.4. Stage-specific Cases of Follicular Lymphoma in France
6.3.3. Italy
6.3.3.1. Total Incident Cases of Follicular Lymphoma in Italy
6.3.3.2. Grade-specific Cases of Follicular Lymphoma in Italy
6.3.3.3. Age-specific Cases of Follicular Lymphoma in Italy
6.3.3.4. Stage-specific Cases of Follicular Lymphoma in Italy
6.3.4. Spain
6.3.4.1. Total Incident Cases of Follicular Lymphoma in Spain
6.3.4.2. Grade-specific Cases of Follicular Lymphoma in Spain
6.3.4.3. Age-specific Cases of Follicular Lymphoma in Spain
6.3.4.4. Stage-specific Cases of Follicular Lymphoma in Spain
6.3.5. The United Kingdom
6.3.5.1. Total Incident Cases of Follicular Lymphoma in the United Kingdom
6.3.5.2. Grade-specific Cases of Follicular Lymphoma in the United Kingdom
6.3.5.3. Age-specific Cases of Follicular Lymphoma in the UK
6.3.5.4. Stage-specific Cases of Follicular Lymphoma in the UK
6.4. Japan
6.4.1. Total Incident Cases of Follicular Lymphoma in Japan
6.4.2. Grade-specific Cases of Follicular Lymphoma in Japan
6.4.3. Age-specific Cases of Follicular Lymphoma in Japan
6.4.4. Stage-specific Cases of Follicular Lymphoma in Japan

7. Treatment

8. Guidelines
8.1. NCCN Guidelines for Patient with Follicular Lymphoma
8.2. ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up: Newly diagnosed and relapsed follicular lymphoma
8.3. Japanese Society of Hematology (JSH) practical guidelines for Follicular lymphoma

9. Unmet Needs

10. Organizations contributing toward Follicular Lymphoma

11. Patient Journey
11.1. A Journey through follicular lymphoma
11.2. Patient Journey: General

12. Case Reports
12.1. Patient Case Study: From Follicular Lymphoma to DLBCL
12.2. Diagnostic Workup for Follicular Lymphoma
12.3. A case study of t(14;22)(q32;q11) involving immunoglobulin heavy and light chain in follicular lymphoma

13. Appendix
13.1. Bibliography
13.2. Report Methodology

14. DelveInsight Capabilities

15. Disclaimer

16. About DelveInsight



List of Figures


Figure 1: SWOT Analysis
Figure 2: Origin of B-cell Lymphomas
Figure 3: Grading of follicular lymphoma
Figure 4: Ann Arbor Classification
Figure 5: Transformation in Follicular Lymphoma
Figure 6: Pathogenesis of Follicular Lymphoma
Figure 7: Stepwise Evolution of Follicular Lymphoma
Figure 8: Model of Microenvironment in Follicular Lymphoma
Figure 9: Transformation in Follicular Lymphoma
Figure 10: Incident Patient Population of Follicular Lymphoma in 7MM (2017–2030)
Figure 11: Total Incident Cases of Follicular Lymphoma in the United States (2017–2030)
Figure 12: Grade-specific Cases of Follicular Lymphoma in the United States (2017–2030)
Figure 13: Age-specific Cases of Follicular Lymphoma in the United States (2017–2030)
Figure 14: Stage-specific Cases of Follicular Lymphoma in the United States (2017–2030)
Figure 15: Total Incident Cases of Follicular Lymphoma in Germany (2017–2030)
Figure 16: Grade-specific Cases of Follicular Lymphoma in Germany (2017–2030)
Figure 17: Age-specific Cases of Follicular Lymphoma in Germany (2017–2030)
Figure 18: Stage-specific Cases of Follicular Lymphoma in Germany (2017–2030)
Figure 19: Total Incident Cases of Follicular Lymphoma in France (2017–2030)
Figure 20: Grade-specific Cases of Follicular Lymphoma in France (2017–2030)
Figure 21: Age-specific Cases of Follicular Lymphoma in France (2017–2030)
Figure 22: Stage-specific Cases of Follicular Lymphoma in France (2017–2030)
Figure 23: Total Incident Cases of Follicular Lymphoma in Italy (2017–2030)
Figure 24: Grade-specific Cases of Follicular Lymphoma in Italy (2017–2030)
Figure 25: Age-specific Cases of Follicular Lymphoma in Italy (2017–2030)
Figure 26: Stage-specific Cases of Follicular Lymphoma in Italy (2017–2030)
Figure 27: Total Incident Cases of Follicular Lymphoma in Spain (2017–2030)
Figure 28: Grade-specific Cases of Follicular Lymphoma in Spain (2017–2030)
Figure 29: Age-specific Cases of Follicular Lymphoma in Spain (2017–2030)
Figure 30: Stage-specific Cases of Follicular Lymphoma in Spain (2017–2030)
Figure 31: Total Incident Cases of Follicular Lymphoma in the United Kingdom (2017–2030)
Figure 32: Grade-specific Cases of Follicular Lymphoma in the United Kingdom (2017–2030)
Figure 33: Age-specific Cases of Follicular Lymphoma in the UK (2017–2030)
Figure 34: Stage-specific Cases of Follicular Lymphoma in the UK (2017–2030)
Figure 35: Total Incident Cases of Follicular Lymphoma in Japan (2017–2030)
Figure 36: Grade-specific Cases of Follicular Lymphoma in Japan (2017–2030)
Figure 37: Age-specific Cases of Follicular Lymphoma in Japan (2017–2030)
Figure 38: Stage-specific Cases of Follicular Lymphoma in Japan (2017–2030)
Figure 39: High tumor burden criteria in FL [Groupe d’Etude des Lymphomes Folliculaires (GELF)]
Figure 40: Follicular Lymphoma-specific International Prognostic Index’ (FLIPI) risk factors
Figure 41: Treatment Algorithm
Figure 42: Standard first-line therapy of Follicular Lymphoma
Figure 43: Overview of evidence-based staging, prognostic tools and strategies and treatment of FL
Figure 44: Follow-up Care for FL
Figure 45: Guidelines for Follicular Lymphoma
Figure 47: Unmet Needs of Follicular Lymphoma


List of Tables


Table 1: Summary of Follicular Lymphoma Epidemiology, and Key Events (2017–2030)
Table 2: Prognostic Factors Associated with Follicular Lymphoma
Table 3: Staging of Non-Hodgkin Lymphoma
Table 4: Biological Factors Associated with Follicular Lymphoma Transformation
Table 5: Incident Patient Population of Follicular Lymphoma in 7MM (2017–2030)
Table 6: Total Incident Cases of Follicular Lymphoma in the United States (2017–2030)
Table 7: Grade-specific Cases of Follicular Lymphoma in the United States (2017–2030)
Table 8: Age-specific Cases of Follicular Lymphoma in the United States (2017–2030)
Table 9: Stage-specific Cases of Follicular Lymphoma in the United States (2017–2030)
Table 10: Total Incident Cases of Follicular Lymphoma in Germany (2017–2030)
Table 11: Grade-specific Cases of Follicular Lymphoma in Germany (2017–2030)
Table 12: Age-specific Cases of Follicular Lymphoma in Germany (2017–2030)
Table 13: Stage-specific Cases of Follicular Lymphoma in Germany (2017–2030)
Table 14: Total Incident Cases of Follicular Lymphoma in France (2017–2030)
Table 15: Grade-specific Cases of Follicular Lymphoma in France (2017–2030)
Table 16: Age-specific Cases of Follicular Lymphoma in France (2017–2030)
Table 17: Stage-specific Cases of Follicular Lymphoma in France (2017–2030)
Table 18: Total Incident Cases of Follicular Lymphoma in Italy (2017–2030)
Table 19: Grade-specific Cases of Follicular Lymphoma in Italy (2017–2030)
Table 20: Age-specific Cases of Follicular Lymphoma in Italy (2017–2030)
Table 21: Stage-specific Cases of Follicular Lymphoma in Italy (2017–2030)
Table 22: Total Incident Cases of Follicular Lymphoma in Spain (2017–2030)
Table 23: Grade-specific Cases of Follicular Lymphoma in Spain (2017–2030)
Table 24: Age-specific Cases of Follicular Lymphoma in Spain (2017–2030)
Table 25: Stage-specific Cases of Follicular Lymphoma in Spain (2017–2030)
Table 26: Total Incident Cases of Follicular Lymphoma in the United Kingdom (2017–2030)
Table 27: Grade-specific Cases of Follicular Lymphoma in the United Kingdom (2017–2030)
Table 28: Age-specific Cases of Follicular Lymphoma in the UK (2017–2030)
Table 29: Stage-specific Cases of Follicular Lymphoma in the UK (2017–2030)
Table 30: Total Incident Cases of Follicular Lymphoma in Japan (2017–2030)
Table 31: Grade-specific Cases of Follicular Lymphoma in Japan (2017–2030)
Table 32: Age-specific Cases of Follicular Lymphoma in Japan (2017–2030)
Table 33: Stage-specific Cases of Follicular Lymphoma in Japan (2017–2030)
Table 34: Organizations contributing toward Follicular Lymphoma